Although BCL-XL has been associated with disease progression,12, 19, 32, 33, 34 this is the first study that demonstrates a novel antiapoptotic role for CIP2A in CML pathogenesis and how this can be overcome by selectively targeting BCL-XL. This evidence concerns the gene BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive.